-
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
-
CorMedix (CRMD) announces $85 million public offering
-
CorMedix Inc. Announces Proposed Public Offering of Common Stock
-
CorMedix (CRMD) PT Raised to $17 at RBC Capital; 'Outpatient Strength Likely to Continue in 2H'
-
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
CorMedix (CRMD) PT Raised to $12 as RBC Capital Sees a 'Supportive Setup for DefenCath into '25'
-
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
-
CorMedix (CRMD) PT Lowered to $9 at RBC Capital
-
CorMedix (CRMD) Prices $40M Share and Warrant Offering at $4/sh
-
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
-
CorMedix (CRMD) Announces Proposed Stock and Warrant Offering
-
CorMedix Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Notable Analyst Rating Changes 3/3: (DIS) (INTC) (BWLD) Upgraded; (BA) (NDLS) (AA) Downgraded
-
Notable Analyst Rating Changes 07/24: (RKUS) (UIS) (SEIC) Upgraded; (ANGI) (QCOM) (BA) Downgraded

